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Summary: Immunoenzymometric assays (lEMAs) for human insulin and intact proinsulin were developed
using the amplification system developed by Johannsson et al. (Clin. Chim. Acta 148 (1985) 119 — 124) for
the detection of the enzyme alkaline phosphatase. The detection limit of the assays was 0.8 pmol/1 for
proinsulin and 0.8 pmol/1 for insulin whereas it was 1.8 pmol/1 and 2.3 pmol/1 respectively for the homologous
immunoradiometric assays (IRMA). These assays are superior to immunoradiometric assays in terms of
sensitivity, shelf-life of the labelled antibody and suitability for automation.
Introduction
We have established new monoclonal antibody based
two-site immunoradiometric assays (IRMAs) specific
for insulin, proinsulin, 32 — 33 split and 65 — 66 split
proinsulins (1). These assays have provided new in-
formation concerning the changes of insulin and
proinsulin in Type II diabetes (2). However, the sen-
sitivity of the immunoradiometric assay is barely ad-
equate for the accurate determination of intact proin-
sulin in plasma from fasting normal subjects. In ad-
dition, assays based upon the use of 125I as an antibody
label and cellulose solid phase are not ideal for the
analysis of large numbers of samples. In order to
1) Funding organisations:
French Fondation pour la Formation par la Recherche a
I'lnterface Chimie-Biologie Paris, France
Medical Research Council, London
British Diabetic Association, London
2) Enzymes:
Alcohol dehydrogenase, alcohol :NAD+ oxidoreductase EC
1.1.1.1
Alkaline phosphatase, orthophosphoric-monoester phos-
phohydrolase EC 3.1.3.1.
Diaphorase, dihydrolipoamide:NAD+ oxidoreductase EC
1.8.1.4
Horse radish peroxidase, donor: hydrogen-peroxide oxido-
reductase EC 1.11.1.7
avoid the frequent iodinations necessitated by the use
of 125I-labelled reagents immunoenzymometric assays
(IBMAs) have been developed using an alkaline phos-
phatase-labelled monoclonal antibody and an ampli-
fication system for measurement of the label.
Several methods have been published for labelling
antibodies with alkaline phosphatase2) (3, 4). Conju-
gation has been carried out using glutaraldehyde as
a homobifunctional reagent. However, this method
has the disadvantage of producing highly polymer-
ised, heterogenous conjugates (5). To overcome this
problem we have used a heterobifunctional conjuga-
tion reagent, N-succinimidyl-3-(2-pyridyldithio)-pro-
pionate. The reaction of this compound with proteins
is more easily controlled than that of glutaraldehyde,
and more sensitive assays have been obtained using
antibody-horse radish peroxidase2) conjugates pre-
pared with N-succinimidyl-3-(2-pyridyldithio)-pro-
pionate as compared with glutaraldehyde. The prin-
ciple of the N-succinimidyl-3-(2-pyridyldithio)-pro-
pionate conjugation is to introduce 2-pyridyl-disul-
phide groups into proteins. One of the proteins is then
thiolated by reduction of the 2-pyridyl-disulphide
groups with a reducing agent. 2-Pyridyl-disulphide
groups on one protein and exposed aliphatic thiol
groups on the other are then allowed to react to form
the conjugate.
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By varying the N-succinimidyl-3-(2-pyridyldithio)-
propionate/protein and the alkaline phosphatase/pro
tein ratio different conjugates were obtained as shown
in the first part of our study. In the second part we
report the results obtained in the lEMAs of human
insulin and intact proinsulin. Two monoclonal anti-
bodies were used for each assay, one of them labelled
as described with alkaline phosphatase and the other
coated to a microtitre plate. An enzyme amplification
step was used to obtain a sensitivity greater than that
observed in the immunoradiometric assay. In this
system -nicotinamide adenine dinucleotide phos-
phate, reduced form (NADPH) was first converted
to -nicotinamide adenine dinucleotide (NADH) by
alkaline phosphatase. The NADH was then used as
a cofactor in a cyclic reaction involving the enzymes
diaphorase and alcohol dehydrogenase to alternately
oxidize and reduce the cofactor in parallel with the
reduction of a dye (8, 9).
Materials and Methods
Materials
Human insulin standard was the first IRP (International ref-
erence preparation) coded 66/304. Intact human proinsulin was
supplied by Lilly Research Laboratories, Indianapolis, Indiana
46285, USA (1). F-16 Immuno Module, flat bottom polystyrene
microtitre plates were obtained from Nunc (Roskilde, Den-
mark). Calf intestine alkaline phosphatase was obtained from
Biozyme Laboratories (Blaenavon, Gwent) as a glycerol solu-
tion containing sodium phosphate (50 mmol/1, pH 6.5), MgCl2
(5 mmol/1) and ZnCl2 (0.1 mmol/1), and used without further
purification. The heterobifunctional reagent N-succinimidyl-3-
(2-pyridyldithio)-propionate was from Pharmacia (Uppsala,
Sweden). Diaphorase from pig heart was obtained from Boeh-
ringer Mannheim (Lewes, E Sussex, UK). All other chemicals
and solvents were obtained from Sigma Chemical Co (Poole,
Dorset, UK) or BDH (Poole, Dorset, UK).
Monoclonal antibodies 3B1, 14B and A6 were prepared as
described elsewhere (1). The IgG fraction used was prepared
from the ascites fluid by precipitation with saturated ammo-
nium sulphate (400 g/1) and affinity chromatography on DEAE
Affigel Blue (10) or an Hydroxylapatite column (11). The purity
of monoclonal antibodies was assessed by electrophoresis on a
10% sodium dodecyl sulphate polyacrylamide gel (SDS PAGE).
The only protein bands visualized after staining with Coomassie
Brilliant Blue were those of the IgG light and heavy chains.
Buffers (see table 1)
Tab. 1. Buffers used
A Sodium phosphate, 0.1 mol/1, pH 7.5; 0.1 mol/1 NaCl
B Sodium acetate, 0.1 mmol/1
C Triethanolamine, 0.1 mol/1, pH 7.0; 0.1 mol/1 NaCl,
1 mmol/1 MgCl2, 0.1 mmol/1 ZnCl2, 3 mmol/1 NaN3
E Tris, 0.01 mol/1, pH 8.5; 0.1 mol/1 NaCl, 3 mmol/1 NaN3
F Sodium barbitone/HCl, 0.05 mol/1, pH 8.0; 0.09 mol/1
NaCl, 0.015 mol/1 NaN3, 73 μιηοΐ/ΐ bovine serum albumin
Conjuga t ion method
a) Derivatization of the enzyme
To a solution of alkaline phosphatase (3.9 g/1) in buffer A
was added a known molar excess of N-succinimidyl-3-(2-
pyridyldithio)-propionate (10 mmol/1 fresh solution in ab-
solute ethanol). Following a reaction period of 30 min the
reaction mixture was subjected to gel filtration using PD-10
Sephadex G-25 (Pharmacia, Uppsala, Sweden) equilibrated
in buffer A. The number of 2-pyridyl-disulphide groups
coupled was determined by measuring the release of thio-
pyridone following reduction of the disulphide bond (6).
b) Derivatization of the monoclonal antibodies
To a solution of monoclonal antibody 3B1 (6.4 g/1 in buffer
A) was added the chosen molar excess of N-succinimidyl-3-
(2-pyridyldithio)-propionate (same 10 mmol/1 solution in
absolute ethanol). Following a reaction period of about 30
min the reacting mixture was subjected to gel filtration using
PD-10 Sephadex G-25 equilibrated in buffer B. The protein
fractions were pooled and the resulting solution concen-
trated by freeze-drying.
The concentrated solution of modified 3B1 (about 1 g/1) was
then treated with a solution of dithiothreitol (0.5 mol/1 in
buffer B) at a final concentration of 25 mmol/1. The reaction
solution was mixed and left at room temperature for 30
min. Excess reagent, oxidized reagent and the product pyr-
idine 2-thione were removed by passing the mixture through
the gel filtration PD-10 Sephadex G-25 column using buffer
A as eluent.
c) Protein coupling
Immediately after the reduction step, the pooled fraction of
modified 3B1 monoclonal antibody was added to the one
of modified enzyme in a known molar ratio. The resulting
solution was further concentrated to about 1.5 g/1. The
reaction time was 18 —24 h at 24 °C. The coupling solution
was then passed down a gel filtration column Sephadex G-
200 (12 χ 1.5 cm) equilibrated in buffer A. The pooled
fraction containing conjugated antibody was further purified
on a FPLC Superose ™6 (Pharmacia) column using buffer
C as eluent. The column was run at a flow rate of 0.3 ml/
min and 0.5 ml fractions were collected. The fractions con-
taining conjugate were pooled and concentrated.
Protein determinations were performed using the Bio-Rad
protein assay (Βίο-Rad Laboratories GmbH, W-8000
M nchen 50, Germany). The enzyme activity of the conju-
gate was measured using /?-nitrophenyl phosphate as sub-
strate and the antigen binding activity of the conjugate was
tested in a two-site assay of insulin (either on microtitre
plates or in Eppendorf tubes) as described below. The con-
jugate was stored at 4 °C in buffer A or C containing bovine
serum albumin (80 μιηοΐ/ΐ) and NaN3 (3 mmol/1).
Measurement of enzyme ac t iv i ty
Alkaline phosphatase activity of column eluate fractions was
determined using p-nitrophenyl phosphate as substrate (12).
The colour development was followed by continuous measure-
ment at 405 nm using a Vmax computer-controlled microplate
reader (Molecular Devices, California).
In the insulin and proinsulin assays the alkaline phosphatase
activity was measured using the amplification system (8, 9),
with the change in absorbance at 490 nm measured continu-
ously.
Measurement of antigen b inding abil i ty
This was carried out using radiolabelled human insulin (gift
from Eli Lilly) and cellulose sheep anti-mouse IgG immunoad-
sorbent to precipitate the complexes formed between the con-
jugated monoclonal antibody and insulin (13).
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I m m u n o e n z y m o m e t r i c assays
Microtitre plates were coated with monoconal antibody A6 and
14B at 10 or 50 mg/1 respectively in coating buffer E. Mono-
clonal antibody solution (200 μΐ per well) was added to the
microtitre plate and incubated overnight at 4 °C. The coated
strips were then washed three times with 0.5 ml/1 Tween 20 in
buffer E, then blocked by incubating with 147 μιηοΐ/ΐ bovine
serum albumin solution (500 μΐ per well) in buffer E for 1 to
3 h at room temperature or overnight at 4 °C. The plate was
then washed (400 μΐ per well) twice with buffer F, diluted 'Λ
(v/v) and containing 5 ml/1 Tween 20, and once in buffer F,
diluted 'Λ (v/v). This same washing procedure was used during
the assay. The coated wells were stored filled with 300 μΐ buffer
E at 4 °C.
a) Insulin assay
The assay for human insulin was carried out using alkaline
phosphatase-conjugated 3B1 monoclonal antibody in a two-
step assay. In this procedure, sample (25 μΐ), mouse serum
(3 μΐ) and 735 μηιοΙ/1 bovine serum albumin buffer F (75
μΐ) were added to 14B monoclonal antibody coated wells
and incubated overnight at 4 °C. After aspiration of the
solution, 100 μΐ conjugate at the appropriate optimum di-
lution in buffer F (0.03 μg/l for conjugate IV) was added
and incubated overnight at 4 °C. The solution was aspirated
and the wells washed (as described previously). The bound
enzyme was detected using the amplification system. Stand-
ards were diluted in 735 μηιοΐ/l bovine serum albumin in
buffer F.
b) Proinsulin assay
The proinsulin determination was carried out as described
above with alkaline phosphatase-conjugated-3Bl mono-
clonal antibody, but with A6 monoclonal antibody coated
wells and using 10 μΐ mouse serum per well.
I m m u n o r a d i o m e t r i c assays
These assays were carried out as described (1) using plasma
samples diluted 'Λ v/v in 735 μπιοΙ/1 bovine serum albumin in
buffer F.
Results
Conjugate pur i f ica t ion
After conjugation the mixture contained a variety of
heteropolymers, free antibody and enzyme. The free
antibody competing with the labelled antibody would
reduce the sensitivity of the assay, whereas the free
enzyme might increase the background reaction. Pu-
rification was carried out in FPLC Superose ™6
column (Pharmacia, Uppsala, Sweden) allowing the
separation of the conjugates (relative molecular mass
Mr 250 000 and above) from the starting uncoupled
enzyme and antibody (fig. 1).
Variat ion of conjugat ion condi t ions
The conjugates listed in table 2 have been prepared.
The two critical variables of the conjugation process
are the molar ratios of 2-pyridyl-disulphide/IgG, 2-
pyridyl-disulphide/enzyme. 2-Pyridyl-disulphide re-
presents the chemical group introduced by reaction














Fig. 1. Fractionation of an alkaline phosphatase-3Bl mono-
clonal antibody conjugate on a FPLC column of Su-
perose ™6.
The purification was carried out using buffer C as
eluent. The reading at 405 nm indicates the amount of
enzyme. The unconjugated enzyme and 3B1 monoclonal
antibody eluated in fraction No. 23.






























(1) measured value determined by quantifying the amount of
pyridine-2-thione (PDP) released by reduction with dithio-
threitol
(2) molar excess of N-succinimidyl-3-(2-pyridyldithio)-propion-
ate (SPDP) used versus the concentration of 3B1 monoclonal
antibody
(3) corresponds to the enzyme activity per weight of protein in
the conjugate in ΔΑ/min per mg
The effect of the number of 2-pyridyl-disulphide
groups on alkaline phosphatase enzymatic activity
and 3B1 monoclonal antibody binding activity is
shown in figure 2. It is apparent that introducing
more than 15 2-pyridyl-disulphide groups for alkaline
phosphatase and 18 for 3B1 monoclonal antibody
reduces their respective activity to less than 50%.
The purification profile of the prepared conjugates on
the Superose ™6 column revealed the polydisperse
nature of the conjugates. Conjugate IV exhibited a
larger range of relative molecular mass. These con-
jugates were compared in a two-site assay for insulin
at a dilution presenting either similar enzymatic ac-
tivity (fig. 3a) or similar protein content (fig. 3b). In
both experiments the polydisperse conjugate IV gave
the greatest increase over background. This conjugate
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Number of 2-pyridyldisulphide groups introduced
Fig. 2. Effect of N-succinimidyl-3-(2-pyridyldithio)-propionate
modification on alkaline phosphatase enzyme activity
(closed circles) and 3B1 insulin binding ability (open
circles).
Abscissa: number of 2-pyridyl-disulphide groups intro-
duced on the enzyme or monoclonal antibody.
Ordinate: percentage of enzymatic activity measured at
490 nm; percentage of 125I-insulin binding activity in the
absence of conjugation. The percentage of 125I-insulin















Fig. 3. Standard curves for IBM A of human insulin obtained
by using conjugates I to IV (tab. 1) at
(a) similar enzyme activity (ΔΑ/min = 0.16 — 0.18) for
10 μΐ of conjugate dilution) and
(b) similar protein content (0.05 μg/l).
Conjugate I (open squares), II (open circles), III (closed
circles), IV (closed squares).
was used for the lEMAs of human insulin and intact
proinsulin. A more precise characterisation and com-
parison of the different conjugates is very difficult,
due to the great heterogeneity of the large molecular
weight species and to the inability to determine the
ratio of enzyme to antibody when either or both may
be partially inactivated.
Sensitivity of IBM As
The assays detected 0.8 pmol/l or 20 attomol per well
for human insulin and 0.8 pmol/l or 20 attomol per
well for human intact proinsulin (mean + 3 standard
deviations (SD) of the zero signal). These detection
limits were lower than those of the homologous IR-
MAs, which were 2.3 pmol/l or 115 attomol per tube
and 1.8 pmol/l or 90 attomol per tube, respectively
(6).
Figures 4 and 5 show typical standard curves for
IEMA of human insulin and intact proinsulin. In the
former assay the cross-reactivities with intact proin-
sulin and 32 — 33 split proinsulin were 5% at concen-
trations up to 200 pmol/l. In the proinsulin IEMA,
the cross-reactivity of insulin was < 1 % and that of








Fig. 4. Log-log representation of the standard curve for IEMA
of human insulin. Standard deviations are shown on
the graph by the vertical bars. The coefficients of vari-
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Proinsulin [pmol/l]
1000
Fig. 5. Log-log representation of the standard curve for IEMA
of human intact proinsulin.
Standard deviations are shown on the graph by the
vertical bars. The coefficients of variation were between
4.2 and 11.7%.
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We compared the insulin concentrations of 85 plasma
samples obtained by IEMA with those obtained by
IRMA. The regression equation was (insulin) IEMA
= 1.14 (insulin) IRMA - 3.0, r = 0.98, indicating
good agreement between the two methods (fig. 6).
Comparison of proinsulin concentrations measured
by IEMA with those measured by IRMA also showed
acceptable agreement (fig. 7). The regression equation
was (proinsulin) IEMA = 1.04 (proinsulin) IRMA
-0.30, r = 0.97, n = 115. Two patients' plasmas
gave grossly aberrant proinsulin results by IEMA and
by IRMA. In both cases the IEMA proinsulin con-
centration reverted to the concentration measured by
IRMA after incubation with goat antiserum to human
IgG, Ig A or IgM (Atlantic Antibodies). These plasmas
showed considerable non-linearity on serial dilution
in 735 μπιοΐ/ΐ bovine serum albumin in buffer F when
assayed by IEMA. Increasing the concentration of
mouse serum in the reaction mixture and use of a
Fab conjugate had no effect on the IEMA result. A
screening test based on monoclonal antibody 3B1 for
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Fig. 6. Comparison of the human insulin concentrations deter-
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Fig. 7. Comparison of the human proinsulin concentrations
determined by IRMA and IEMA in 115 plasma sam-
ples.
Precision
The intra-run variance was tested by assaying four
samples twenty times in one assay. The inter-run
variance was estimated by analysis of four samples in
duplicate in consecutive runs. The reproducibility of
these assays was acceptable (tab. 3).











































































Analytical recovery and dilut ion
The recovery of human insulin (50 — 200 pmol/1) from
plasma, assessed by the addition of known quantities
of insulin to plasma, was 99% (range 96 — 101%). In
an experiment carried out with plasma of three normal
fed subjects we observed a linear correlation between
the degree of dilution (from neat to 1:16) and the
measured concentration. The recovery of human
proinsulin (6 — 26 pmol/1) from plasma was 98%
(range 88-112%). The serial dilution of 5 plasmas
containing high concentrations of proinsulin also
showed good linearity.
Discussion
The present results show that the combination of
alkaline phosphatase labelling of antibodies with the
amplification (cycling) system devised by Johannsson
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et al. (8) is capable of producing insulin and intact
proinsulin assays with lower detection limits than
those achieved in immunoradiometric assays using
the same antibodies. We have found that 10—15
molecules of the heterobifunctional conjugation re-
agent N-succinimidyl-3-(2-pyridyldithio)-propionate
can be linked to alkaline phosphatase or to a mono-
clonal antibody before either protein becomes 50%
inactivated. Using a variety of conditions in which
the ratios of N-succinimidyl-3-(2-pyridyldithio)-pro-
pionate to enzyme or antibody were varied, as well
as the ratio of enzyme to antibody, a series of con-
jugates was prepared with a six fold range of the
specific activity of the conjugate. It was observed that
the performance of a conjugate in an assay was not
simply a function of its specific activity. We have not
exhaustively investigated the conditions necessary for
optimising the production of conjugates for the as-
says, though standard curves were produced by con-
jugates prepared in a variety of ways, suggesting that
the overall approach to conjugation is reasonably
robust. Using such conjugates we have developed
lEMAs for insulin and for proinsulin, the former
having been in routine use for over a year. Further
investigations are underway to determine the cause
of the discrepant results in the proinsulin assay which
may be due to interfering antibodies (14). A simple
screening test allows such samples to be identified so
that they can be treated by immunoprecipitation be-
fore assay. In view of the lower detection limit, longer
shelf-life of the labelled antibody and greater ease of
automation we believe that such assays are superior
to those achieved by direct labelling of monoclonal
antibodies with 125I.
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